At Tri-Con, UCSF's Charles Chiu discussed validation of a metagenomic NGS test as well as a new project to develop an RNA sequencing panel for Lyme disease.
The study involved 11 sites and 1,560 prospectively collected patient samples and demonstrated high overall positive and negative percent agreement with comparator assays.
A Centers for Disease Control and Prevention-operated lab had its permit for working with dangerous pathogens suspended due to safety violations, USA Today reports.
The high-throughput system is now approved with the firm's Blood Culture ID, Gastrointestinal, Meningitis/Encephalitis, and the previously approved Respiratory Panel.
Researchers sequenced and analyzed the negative-sense RNA tilapia lake virus, implicated in large die-offs of farmed and wild tilapia in Israel and Ecuador.
The FilmArray ME Panel received a de novo clearance from the US Food and Drug Administration in October.
The FilmArray ME Panel is the first nucleic acid amplification test to detect multiple pathogens from a single cerebrospinal fluid sample.
The US Centers for Disease Control and Prevention is investigating the handling of samples at four Department of Defense labs, the New York Times reports.
The UCSF Center for Next-Gen Precision Medicine Diagnostics will use NGS to develop technology to diagnose meningitis and encephalitis.
Sequence and other data suggest a squirrel-borne bornavirus may be behind three mysterious deaths in Germany.
Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.
In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.